Skin explant model of human GVHD: Prediction of clinical outcome and correlation with biological risk factors  by Wang, X.-N. et al.
in the intestine, liver and skin on day 60. All of BMT recipients
showed complete donor engraftment. Examination of T cells in the
spleen on day 14 showed that CD100 / T cells expanded
fourfold less than wild type (P  .01). Together our data show that
Sema4D is a co-stimulatory molecule that modulates T cell allo-
geneic responses both in vitro and in vivo and may represent a
novel target for the prevention of GvHD (Table 1).
Table 1. CD100/ vs Wild Type T Cell Transplant Outcomes
Day post
Transplant
wt T
Cells n
CD100/
T Cells n
P
Value
GvHD clinical
score
60 4.6  0.8 6 1.8  0.2 6 <.02
Survival 60 67% 6 100% 6 .08
Liver pathology 60 17.0  1.5 4 9.0  1.3 4 <.01
Skin pathology 60 1.5  0.2 4 0.8  0.2 4 .02
Intestinal
pathology
60 7.8  0.8 8 4.8  1.0 8 .03
T cell expansion
(106)
14 3.95  0.78 5 0.83  0.16 5 <.01
95% conﬁdence interval.
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EXTRACORPOREAL PHOTOPHERESIS (ECP) STIMULATES THE GENER-
ATION OF REGULATORY T CELLS
Strobl, F.J., Huber, J., Krutsick, A., Campbell, K.A., Peritt, D.
THERAKOS, Inc., Exton, PA.
Extracorporeal photopheresis (ECP) involves the reinfusion of
autologous, apoptotic peripheral blood leukocytes treated ex vivo
with 8-methoxypsoralen (8-MOP) and UVA light. ECP is ap-
proved for the palliative treatment of cutaneous T cell lymphoma.
ECP has also shown promise as a treatment for other immune-
mediated inﬂammatory disorders suggesting a common immuno-
logic pathway may be involved in it’s mechanism of action. Several
investigators including ourselves have recently provided in vivo
evidence to suggest that the delivery of ECP-treated apoptotic cells
modulates immune responses, in part, through the generation of
regulatory T cells. In vitro studies have also demonstrated that
activation of naive T cells in the presence of antigen presenting
cells (APCs) that have previously engulfed ECP-treated apoptotic
cells leads to the generation of a T cell population that can suppress
syngeneic T cell proliferation and function. In this study, we
expand the scope of these original ﬁndings by demonstrating that
co-incubation of naive CD4 T cells with ECP-treated peripheral
blood mononuclear cells also results in the development of a
regulatory T cell phenotype. ECP-mediated generation of regula-
tory T cells is dependent on APCs and can be reversed by the
addition of interleukin-2 (IL-2). These regulatory T cells actively
proliferate in response to concanavalin-A (Con A) but do not
secrete signiﬁcant levels of pro-inﬂammatory cytokines. Transfer
of these regulatory T cells to a secondary MLR reaction results in
the inhibition of syngeneic responder T cell proliferation. Addi-
tional studies are underway to characterize these cells and deter-
mine their suppressive capacity in vivo. Collectively, these results
demonstrate that ECP-treated apoptotic cells are capable of mod-
ulating other immune cells, in part, through the generation of
regulatory T cells. Regulatory T cells have been implicated in the
control of a variety of immune-mediated inﬂammatory diseases. It
is hoped that a better understanding of the mechanism of action
behind ECP will help to deﬁne more efﬁcacious and cost-effective
treatment regimens.
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ROLE FOR ACTIVATED DONOR NK CELLS IN PROTECTION FROM
ACUTE, LETHAL GVHD AND THE PROMOTION OF ENGRAFTMENT IN A
PARENTAL STRAIN3F1-HYBRID MODEL
Ellison, C.A.1,2, Fischer, J.M.M.1, Gartner, J.G.1,3 1. Department of
Pathology, University of Manitoba, Winnipeg, MB, Canada; 2. Mani-
toba Blood and Marrow Transplant Program, CancerCare Manitoba,
Winnipeg, MB, Canada; 3. Department of Immunology, University of
Manitoba, Winnipeg, MB, Canada.
The effects of donor NK cells in allogeneic bone marrow trans-
plantation and the development of GVHD remains controversial.
Using the C57BL/63(C57BL/6  DBA/2)F1-hybrid model of
acute GVHD, we performed experiments in which the donor mice
were stimulated with polyinosinic:polycytidylic acid (poly I:C) be-
fore the grafts were harvested. Poly I:C is a potent activator of NK
cell cytotoxicity and an inducer of interferon production. In some
of these experiments, we also removed the adherent cells from the
graft prior to transplantation. The following four experimental
groups were established: (1) recipients of unmanipulated grafts
from unstimulated donors; (2) recipients of unmanipulated grafts
from poly I:C-stimulated donors; (3) recipients of non-adherent
grafts from unstimulated donors; and (4) recipients of non-adher-
ent grafts from poly I:C-stimulated donors. The only group in
which protection from acute, lethal GVHD was seen was group
(4), in which 75% of the recipients survived until at least day 90
post-induction. Only 50% of the recipients in group (4) survived
when the graft was depleted of DX5 cells using a magnetic cell
sorter. This was also associated with a marked reduction in the
level of engraftment of total donor cells, as well as donor T cells in
the long-term survivors in group (4). Our ﬁndings show that
recipients of grafts from poly I:C-stimulated donors are only pro-
tected when the adherent cells are removed from the graft but the
precise mechanism through which protection is achieved is not
known. They further show that donor DX5 cells are at least partly
responsible for the protection we observed and that these cells
promote engraftment, particularly of T cells. Supported by an
establishment grant to CAE from the CancerCare Manitoba Foun-
dation.
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SKIN EXPLANT MODEL OF HUMAN GVHD: PREDICTION OF CLINICAL
OUTCOME AND CORRELATION WITH BIOLOGICAL RISK FACTORS
Wang, X.-N.1, Collin, M.1, Sviland, L.2, Marshall, S.R.1,
Jackson, G.H.3, Schulz, U.4, Holler, E.4, Karrer, S.5, Greinix, H.6,
Elahi, F.6, Hromadnikova, I.7, Dickinson, A.M.1 1. University of New-
castle upon Tyne, Newcastle upon Tyne, United Kingdom; 2. Haukeland
Hospital, Bergen, Norway; 3. Royal Victoria Inﬁrmary, Newcastle upon
Tyne, United Kingdom; 4. Department of Haematology and Oncology,
University of Regensburg, Regensburg, Germany; 5. Department of
Dermatology, University of Regensburg, Regensburg, Germany; 6. Med-
ical University of Vienna, Vienna, Austria; 7. Charles University,
Prague, Czech Republic.
A human skin explant model has been used to predict the clinical
outcome and to study the immunopathology of human GVHD.
Whether the model gives the same predictive effect for GVHD in
different haematopoietic stem cell transplant (HSCT) settings has
not been assessed. It is also unknown whether the skin explant
result reﬂects the known biological risk factors for clinical GVHD.
In this present study the skin explant model was used to detect
graft-versus-host reactions (GVHR) in vitro for 225 eligible pa-
tient/donor pairs. Predicted skin GVHR grade was correlated with
the outcome of clinical GVHD as well as the HLAmatching status,
gender mismatches and patient age. In sibling HSCT under either
myeloablative or reduced intensity conditioning a signiﬁcant cor-
relation was observed between the predicted skin GVHR and
clinical GVHD (P  .001 and P  .033 respectively). In HSCT
using unrelated donors the involvement of T cell depletion led to
a sharp increase in false positive GVHR results and no correlation
was observed between the predicted skin GVHR and clinical
GVHD. Skin GVHR grade correlated signiﬁcantly with HLA
matching status (HLA matched sibling pairs, HLA matched unre-
lated pairs and HLA unmatched unrelated pairs). Furthermore
HLA matched sibling pairs with female to male gender mismatch
gave rise to signiﬁcantly higher overall skin GVHR grade and
higher ratio of high vs low grade skin GVHR than the sibling pairs
with all other gender combinations. Patient age was not reﬂected
in the skin explant result. In conclusion, the predictive value of the
skin explant model for aGVHD varies depending on the clinical
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transplant protocols such as the type of GVHD prophylaxis used.
Nevertheless, the skin explant model remains a unique in vitro
system which provides an in situ histopathological read-out for
studying alloreactivity and human GVHD. The model has also the
potential to aid the development of novel prophylaxis and treat-
ment for GVHD.
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INTERFERON-	 THERAPY FOR PATIENTS WITH MOLECULAR RELAPSE
IN LEUKEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
Murai, K., Sugawara, T., Oyake, T., Kowata, S., Numaoka, H.,
Suzuki, K., Ishida, Y. Hematology and Oncology, Iwate Medical Uni-
versity, Morioka, Iwate, Japan.
One of the problems in allogeneic stem cell transplantation
(alloSCT) for acute leukemia (AL) is the recurrence of the disease.
Wilms’ tumor gene (WT1) expression has been reported to be
expressed in leukemic cells and used as a prediction marker of
leukemia relapse after chemotherapy (CT) in patients with AL.
Recently, Ogawa et al. described that the quantitative measure-
ment of WT1 expression in bone marrow cells (BM cells) assisted
the prediction of leukemia recurrence after allo-SCT (Blood 2003).
Several reports showed that interferon 
 (IFN
) administration
was effective in the prevention of leukemia recurrence in patients
after alloSCT. Based on this evidence, we tried to prevent the
recurrence of AL by IFN
 administration in patients with
alloSCT. We reported here three patients with molecular relapsed
AL after alloSCT who received the administration of IFN
 to get
and maintain complete remission (CR). The molecular relapse was
deﬁned as the criteria, described by Ogawa et al. They could not
receive donor lymphocyte infusion (DLI) because of no acceptance
of donor. Case 1 (SI): The patient with refractory AML received
BMT from unrelated donor (uBMT). He began to receive IFN
 (2
MU/m2 , four times per week) on day 84, when the molecular
relapse was diagnosed, and maintained the administration for 1
month. WT1 expression in BM cells decreased rapidly (32003 82
copies/mg RNA). He has achieved CR more than 30 months. Case
2 (TM): The patient with high risk AML received PBSCT from
sibling donor. She began to receive IFN
 (2 MU/m2 , two times
per week) on day 384, when the molecular relapse was diagnosed,
and had kept the administrations for 4 months. WT1 expression in
BM cells decreased rapidly (4100 3 1100 copies/mg RNA). She
has maintained CR for 21 months. Case 3 (HK): The patient with
high risk AML received uBMT. He began to receive IFN
 (2
MU/m2 , two times per week) on day 209, when the molecular
relapse was diagnosed, and had kept the administration for 2
months. WT1 expression in BM cells decreased rapidly (110003
1100 copies/mg RNA). He had maintained CR for 12 months. His
WT1 expression level re-increased on day 366, and a BM aspirate
showed 18.5% leukemic cells on day 387. He again received the
CT and alloSCT. In each case, WT1 expression in BM cells
decreased rapidly. They could keep CR more than 5 months (30,
21 and 5 months). These results strongly suggest that IFN
 might
be useful in treating molecular relapsed leukemia after alloSCT.
171
IMPORTANCE OF DETERMINING TRANSFORMING GROWTH FACTOR
1 PROMOTER ALLELES TO PREDICT EXPRESSION PHENOTYPE AND
ITS POTENTIAL IMPACT ON BONE MARROW TRANSPLANTATION
Shah, R., Selby, S.T., Rahaman, B., Posch, P.E., Hurley, C.K. George-
town University Medical Center, Washington, DC.
Transforming growth factor beta 1 (TGF-1) is a multifunc-
tional cytokine that plays a crucial role in immune regulation.
Three of eight known polymorphic sites in the human TGF-1 5
regulatory and signal peptide regions have been associated with
higher secreted levels of TGF1. These single nucleotide poly-
morphisms (SNPs) have been linked to bone marrow transplant
(BMT) outcome but the results are inconsistent. As each of these
studies examined single SNPs, the conﬂict could be due to differ-
ent linkages between these SNPs and other functional SNPs and
the corresponding phenotypes. A more comprehensive study of
diversity and SNP linkages was undertaken here. Ten novel poly-
morphisms and 14 novel alleles were identiﬁed by sequence char-
acterization of 38 unrelated individuals. The TGF-1 alleles clus-
tered into three phylogenetic groups based on the common
functional SNPs 509C-T and 869T-C suggesting three phe-
notypic groups. However, the 509 and 869 SNP positions
might not be as informative for predicting TGF-1 phenotypes as
suggested by the allelic groups. For example, individuals who carry
allele p014 (intermediate phenotype) are more likely to have a low
production phenotype due to the presence of 915C (decreased
TGF-1 expression) in this allele. This observation highlights why
limited genotyping to predict phenotypes may not be deﬁnitive as
linked SNPs likely affect the expected phenotypes that would be
attributed to single SNPs. To assess impact of TGF-1 promoter
genotype on likelihood of developing and/or severity of graft-
versus-host-disease (GVHD) in bone marrow transplant patients,
we are characterizing 40 unrelated donor/recipient pairs in a pilot
study. The genotype, p001/p003, was frequent (12/17 70.5%) in
recipients with grade 3 and 4 GVHD in comparison to recipients
with GVHD grades 0-2 (7/16 43.7%). These data target certain
TGF-1 promoter alleles for further study.
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THE UNEXPECTED AND DIFFERENTIAL EFFECT OF CYCLOSPORIN A ON
CD56bright AND CD56dim NK CELL EXPANSION, PHENOTYPE, FUNC-
TION AND DEVELOPMENT FROM PROGENITOR CELLS
Wang, H., Lee, A., McCullar, V., Blazar, B.R., Miller, J.S.,
Verneris, M.R. University of Minnesota, Minneapolis, MN.
Following allo-HCT, NK cells play important roles in engraft-
ment, anti-viral responses, GVHD and GVL. Cyclosporine A
(CsA), is frequently administered to prevent or treat GVHD. It is
generally considered that CsA inhibits GVL. To date, little is
known about the impact of CsA on NK cell function. To investi-
gate this, NK cells (from healthy donors) were cultured with IL-2,
IL-15 and either physiological levels of CsA (1 g/ml) or vehicle
control. CsA treated cultures showed reduced NK cell expansion at
one week (4.88 vs. 1.87 fold expansion, n  10). The phenotype of
CsA treated NK cells was markedly different than controls. After
7-10 days of culture with CsA there were signiﬁcantly more
CD56brightCD16 cells and signiﬁcantly less CD56dimCD16 cells
(P  .001 for both). The percentage of KIR receptor (CD158a/h,
CD158b/j and CD158e) expressing cells was signiﬁcantly less in
CsA treated cultures. No changes were detected in NKG2D,
NKp30, NKp44, or NKp46. To further investigate the inﬂuence
of CsA on NK cell subset expansion, freshly isolated NK cells were
stained with CFSE then cultured with CsA or vehicle control for 1
week. Using FACS we monitored CD56dimCD16 and
CD56brightCD16 cell division. There was no difference in the
proliferation of CD56brightCD16 cells between the CsA and con-
trol treated cultures. In contrast, the CsA treated CD56dimCD16
cells had fewer cell divisions, demonstrating that CsA selectively
inhibits CD56dimCD16 cell proliferation. To investigate the cy-
totoxicity of CsA treated NK cells, we performed killing assays.
Surprisingly, we found higher cytotoxicity in CsA treated NK cells
compared to controls (K562, P .05 and Raji, P .05). To further
evaluate CsA treated NK cells, we investigated the intracellular
IFN- secretion following IL-12/IL-18 stimulation. In 5 consec-
utive experiments the percentage of IFN- secreting cells was
higher in CsA treated NK cells (44% vs. 24%, P  .05). Lastly, we
determined the effect of CsA on NK cell differentiation from
progenitor cells (CD34LinCD38) using an in vitro differenti-
ation system. Brieﬂy, progenitor cells were cultured on a murine
feeder cell line (AFT-024) for 42 days in the presence of IL-3,
IL-7, IL-15, SCF and FLT3L  CsA. CsA treated cultures had
less KIR expressing cells compared to controls. Collectively these
results show that physiological levels of CsA results in NK cells
that have less KIR receptors, higher cytotoxicity and more cytokine
secretion.
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